Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 7
2015 6
2016 2
2017 2
2018 2
2019 3
2020 2
2022 5
2023 13
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Intravenous Immune Globulin in Dermatomyositis.
Aggarwal R, Charles-Schoeman C, Schessl J, Bata-Csörgő Z, Dimachkie MM, Griger Z, Moiseev S, Oddis C, Schiopu E, Vencovský J, Beckmann I, Clodi E, Bugrova O, Dankó K, Ernste F, Goyal NA, Heuer M, Hudson M, Hussain YM, Karam C, Magnolo N, Nelson R, Pozur N, Prystupa L, Sárdy M, Valenzuela G, van der Kooi AJ, Vu T, Worm M, Levine T; ProDERM Trial Group. Aggarwal R, et al. N Engl J Med. 2022 Oct 6;387(14):1264-1278. doi: 10.1056/NEJMoa2117912. N Engl J Med. 2022. PMID: 36198179 Clinical Trial.
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative.
Oldroyd AGS, Callen JP, Chinoy H, Chung L, Fiorentino D, Gordon P, Machado PM, McHugh N, Selva-O'Callaghan A, Schmidt J, Tansley SL, Vleugels RA, Werth VP; International Myositis Assessment and Clinical Studies Group Cancer Screening Expert Group; Aggarwal R. Oldroyd AGS, et al. Nat Rev Rheumatol. 2023 Dec;19(12):805-817. doi: 10.1038/s41584-023-01045-w. Epub 2023 Nov 9. Nat Rev Rheumatol. 2023. PMID: 37945774 Review.
Pharmacological management of dermatomyositis.
Griger Z, Nagy-Vincze M, Dankó K. Griger Z, et al. Among authors: nagy vincze m. Expert Rev Clin Pharmacol. 2017 Oct;10(10):1109-1118. doi: 10.1080/17512433.2017.1353910. Epub 2017 Jul 17. Expert Rev Clin Pharmacol. 2017. PMID: 28691537 Review.
[Dermatomyositis-specific antibodies].
Bodoki L, Nagy-Vincze M, Griger Z, Dankó K. Bodoki L, et al. Among authors: nagy vincze m. Z Rheumatol. 2015 May;74(4):363-9. doi: 10.1007/s00393-014-1524-7. Z Rheumatol. 2015. PMID: 25644067 Review. German.
Global disparities in the treatment of idiopathic inflammatory myopathies: results from an international online survey study.
Ziade N, Aoude M, Hmamouchi I, R N, Lilleker JB, Sen P, Joshi M, Agarwal V, Kardes S, Day J, Makol A, Milchert M, Gheita T, Salim B, Velikova T, Edgar Gracia-Ramos A, Parodis I, Nikiphorou E, Chatterjee T, Tan AL, Saavedra MA, Shinjo SK, Knitza J, Kuwana M, Nune A, Cavagna L, Distler O, Chinoy H, Agarwal V, Aggarwal R, Gupta L; COVAD Study Group. Ziade N, et al. Rheumatology (Oxford). 2024 Mar 1;63(3):657-664. doi: 10.1093/rheumatology/kead250. Rheumatology (Oxford). 2024. PMID: 37228012
[Biological therapy in idiopathic inflammatory myopathies].
Bodoki L, Nagy-Vincze M, Griger Z, Péter A, András C, Dankó K. Bodoki L, et al. Among authors: nagy vincze m. Orv Hetil. 2014 Jan 5;155(1):3-10. doi: 10.1556/OH.2014.29787. Orv Hetil. 2014. PMID: 24379090 Review. Hungarian.
Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study.
Naveen R, Nikiphorou E, Joshi M, Sen P, Lindblom J, Agarwal V, Lilleker JB, Tan AL, Salim B, Ziade N, Velikova T, Gracia-Ramos AE, Kuwana M, Day J, Makol A, Distler O, Chinoy H, Traboco LS, Wibowo SAK, Tehozol EAZ, Serrano JR, García-De La Torre I; COVAD Study Group; Aggarwal R, Gupta L, Agarwal V, Parodis I. Naveen R, et al. Rheumatology (Oxford). 2023 Jul 5;62(7):2453-2463. doi: 10.1093/rheumatology/keac661. Rheumatology (Oxford). 2023. PMID: 36413073 Free PMC article.
Higher risk of short term COVID-19 vaccine adverse events in myositis patients with autoimmune comorbidities: results from the COVAD study.
Dey M, R N, Nikiphorou E, Sen P, Saha S, Lilleker JB, Agarwal V, Kardes S, Day J, Milchert M, Joshi M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, Selva O'Callaghan A, Kim M, Chatterjee T, Tan AL, Makol A, Nune A, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Kuwana M, Distler O, Barman B, Singh YP, Ranjan R, Jain A, Pandya SC, Pilania RK, Sharma A, Manoj MM, Gupta V, Kavadichanda CG, Patro PS, Ajmani S, Phatak S, Goswami RP, Chowdhury AC, Mathew AJ, Shenoy P, Asranna A, Bommakanti KT, Shukla A, Pande AR, Chandwar K, Pauling JD, Wincup C, Üsküdar Cansu D, Zamora Tehozol EA, Rojas Serrano J, García-De La Torre I, Del Papa N, Sambataro G, Fabiola A, Govoni M, Parisi S, Bartoloni Bocci E, Sebastiani GD, Fusaro E, Sebastiani M, Quartuccio L, Franceschini F, Sainaghi PP, Orsolini G, De Angelis R, Danielli MG, Venerito V, Traboco LS, Hoff LS, Kusumo Wibowo SA, Tomaras S, Langguth D, Limaye V, Needham M, Srivastav N, Yoshida A, Nakashima R, Sato S, Kimura N, Kaneko Y, Loarce-Martos J, Prieto-González S, Gil-Vila A, Gonzalez RA, Chinoy H, Agarwal V, Aggarwal R, Gupta L; COVAD Study Group. Dey M, et al. Rheumatology (Oxford). 2023 May 2;62(5):e147-e152. doi: 10.1093/rheumatology/keac603. Rheumatology (Oxford). 2023. PMID: 36282492 Free PMC article. No abstract available.
41 results